Previous close | 4.1900 |
Open | 4.1900 |
Bid | 3.9600 x 300 |
Ask | 4.0000 x 100 |
Day's range | 3.9400 - 4.2350 |
52-week range | 1.0800 - 5.0000 |
Volume | |
Avg. volume | 1,310,037 |
Market cap | 208.276M |
Beta (5Y monthly) | 1.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9300 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.50 |
We feel now is a pretty good time to analyse G1 Therapeutics, Inc.'s ( NASDAQ:GTHX ) business as it appears the company...
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 1
RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET. The webcast of the event will be accessible on the Events & Presentations page of https://www.g1therapeutics.com/. About G1 TherapeuticsG1 Therapeutics, In